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ABSTRACT
Chronic breathlessness, persistent and disabling despite optimal treatment of underlying causes, is a
prevalent and frightening symptom and is associated with many emergency presentations and admission
to hospital. Breathlessness management techniques used by paramedics may reduce the need for
conveyance to hospital. The Breathlessness RElief AT HomE study (BREATHE) aims to explore the
feasibility of conducting a definitive cluster randomised controlled trial (cRCT) for people with acute-on-
chronic breathlessness who have called an ambulance, to evaluate the effectiveness and cost-effectiveness
of a paramedic-administered non-pharmacological breathlessness intervention.
The trial is a mixed-methods feasibility cRCT. Eight paramedics will be randomised 1:1 to deliver either
the BREATHE intervention in addition to usual care or usual care alone at call-outs for acute-on-chronic
breathlessness. Sixty participants will be recruited to provide access to routine data relating to the index
call-out with optional follow-up questionnaires at 14 days, 1 month and 6 months. An in-depth interview
will be conducted with a subgroup. Feasibility outcomes relating to recruitment, data quality (especially
candidate primary outcomes), and intervention acceptability and fidelity will be collected as well as
providing data to estimate a sample size for a definitive trial.
Yorkshire and The Humber–Sheffield Research Ethics Committee approved the trial protocol (19/YH/
0314). The study results will inform progression to, or not, and design of a main trial according to
predetermined stop-go criteria. Findings will be disseminated to relevant stakeholders and submitted for
publication in a peer-reviewed journal.
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Acute-on-chronic breathlessness initiates many emergency presentations. The BREATHE
protocol describes a feasibility, cluster randomised controlled trial of a paramedic breathlessness
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Chronic breathlessness, persistent and disabling despite treatment of underlying causes [1], is a prevalent
and often frightening feature in cardiorespiratory disease(s). It is more common in older adults [2] with
widespread impacts for patients, family carers and health systems [1–3]. Acute worsening of chronic
breathlessness (acute-on-chronic breathlessness) is mostly triggered by physical and/or emotional exertion
[4]. Tailored non-pharmacological interventions are effective [5] and include breathing retraining,
relaxation and anxiety management techniques, pacing and prioritisation [6], and cool facial airflow, for
example, from a hand-held, battery-operated fan [7].
Severe episodes of acute-on-chronic breathlessness may be caused by a worsening/complication of the
underlying disease, or when distress perpetuates and magnifies the symptom [8]. Acute-on-chronic
breathlessness often triggers emergency use of health services [9]. However, approximately a third of those
attending the emergency department (ED) because of acute-on-chronic breathlessness do not need
hospital admission, and some ED attendances might be preventable [9]. Estimates of breathlessness as a
primary reason for adult ED presentations range between 2.7% and 9% [10–13]. In one UK study,
acute-on-chronic breathlessness was a reason for ED conveyance by ambulance in 20% of attendances [9].
The presence and intensity of breathlessness on ED arrival predicts hospital admission [14] and return
presentations [15].
For many, the ED is necessary. For others, particularly those with advanced disease where palliation is the
priority, the ED is less likely to be the optimal place for care if community-based care is working
effectively [16]. People with recurrent acute-on-chronic breathlessness may have anxiety playing a
significant role, and for whom targeted community-based management plans may reduce the need for ED
attendances [17].
The American Thoracic Society (ATS) recommends a dual approach to breathlessness management [18].
Initial management should be given by first responders, using evidence-based non-pharmacological
breathlessness interventions. In addition, patients and carers should receive education and training in
appropriate self-management techniques to reduce the need for external help. These techniques should be
reinforced at every breathlessness encounter [18]. For some, an acute worsening of breathlessness can
become a “teachable moment” [19]. Carers may also learn techniques by observing skilled paramedics [20]
in this teachable moment. With this approach, more people with acute-on-chronic breathlessness might be
managed safely in the community or, if hospital admission is needed, have their breathlessness brought
under control more quickly.
Study aim and objectives
The Breathlessness RElief AT HomE study (BREATHE) aims to define the feasibility and desirability of
conducting a definitive cluster randomised controlled trial (cRCT) for people with acute-on-chronic
breathlessness to evaluate the effectiveness and cost-effectiveness of a paramedic-administered,
non-pharmacological breathlessness intervention.
Recruitment and retention rates
The feasibility of recruiting the required number of paramedic-participants and patient-participants
needed for a definitive trial within a reasonable trial timeline will be assessed. This will include the
acceptability to be randomised within the paramedic-participants and the feasibility of consenting the
patient-participants within the time constraints of clinical priorities during an acute call-out.
Intervention
The acceptability, adherence and fidelity, and safety of the BREATHE intervention will be assessed.
Data quality
The quality of data collected during the paramedic call-out in terms of amount and pattern of missing
data will be assessed.
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Outcomes
The most clinically relevant primary outcome for the definitive trial will be determined by assessing data
completion of candidate primary outcomes, qualitative interview data relating to patient views on
relevance and acceptability, and the variability around baseline measures. Using the variability values for
primary outcome finally chosen, a sample size estimation for a definitive trial will be made.
Implementation issues
Any issues that could impact the implementation of the intervention will be identified, and this
information will be used to inform the development of the definitive trial. This will include the
development of training materials for paramedics and subsequent implementation into clinical practice.
Methods and analysis
Design
BREATHE is a mixed-methods feasibility cRCT with an embedded normalisation process theory-based
(NPT) study. Paramedics, who will act as the cluster unit, will be randomised 1:1 to deliver either the
BREATHE intervention plus usual care or usual care only during call-out to patients experiencing
acute-on-chronic breathlessness.
This feasibility trial is community-based, with paramedics recruited from ambulance stations within one
regional ambulance service. The first paramedic-participants were randomised in January 2020, with the
first patient-participant recruited in February 2020.
The trial procedures for patient-participants are outlined in the study flowchart (figure 1) and schedule of
events (table 1).
Study population
Paramedic-participants will be recruited from ambulance stations in one geographical region through
advertisement and will be willing to undergo training in study measures, processes and the BREATHE
intervention as required. All paramedics in the service are trained in the clinical assessment of the acutely
unwell patient, with expertise in making hospital conveyance decisions either immediately or at the end of
their visit in accordance with nationally agreed Joint Royal College Ambulance Liaison Committee
( JRCALC) guidelines on initial assessment and oxygen use [21].
Eligible patients will be in their normal home environment receiving a 999 ambulance response from
participating paramedics because of breathlessness. They will: have a self-reported diagnosis of a
cardiorespiratory disease (including intra-thoracic malignancy); experience chronic breathlessness (defined
as short of breath most days in the last 3 months or longer); and be able to give retrospective consent at
the end of the call-out. Patients needing immediate life-saving intervention/transfer to the ED in the
paramedic’s clinical judgement are ineligible. They will also be excluded if they are currently enrolled on
the trial or have previously participated. Carers present at call-out of any patient-participants consenting
to be approached by the study team will be invited to take part in an interview.
Recruitment and consent
Paramedic-participants
The first eight paramedics to confirm a willingness to participate having read the paramedic-participant
information sheet (PIS) will be invited to attend study initiation training. In the event of paramedic
withdrawal prior to the training session, a paramedic from the waiting list will be invited. At the beginning
of the training session an opportunity to ask any questions will be provided prior to being consented into
the trial. Those randomised to BREATHE intervention plus usual care will also receive intervention training.
Patient-participants
Patient-participants will be identified and screened by participating paramedic-participants during the
call-out. A two-step process will be adopted to patient-participant recruitment. From the beginning of the
call-out, all paramedics will start recording the numerical rating scale (NRS) values of breathlessness
severity. Paramedics randomised to deliver the BREATHE intervention will make an initial assessment of
eligibility on arrival and deliver the intervention to those considered appropriate. At the end of the visit,
whether staying at home, or being transferred, patients will be screened for eligibility, given the patient PIS
and invited to participate. If willing, immediate written or witnessed verbal retrospective consent will be
taken to use routinely collected clinical data from the index visit (Day 0), including the NRS measures,
and details of any further call-outs in the subsequent 48 h.
Patient-participants can opt to be contacted about participation in further follow-up. Those agreeing to
contact will be phoned by a member of the research team to discuss the purpose and processes of the
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follow-up and have the follow-up interview/questionnaires arranged on Day 14 (±7 days). In the event of
admission to hospital at the initial visit, this would occur at the first opportunity after discharge home
(maximum by Day 21). The patient PIS will be given to the patient-participant (and carer-participant if
present) at the time of the visit and reviewed together to allow time to ask further questions before
consent is taken.
Randomisation and blinding
Following consent, paramedics will be randomly allocated (1:1, random permuted blocks) using a
commercial web-based randomisation system (REDCap Cloud) to BREATHE intervention plus usual care
or usual care only.
Paramedic recruitment
Randomisation
BREATHE intervention + usual care
BREATHE intervention training
Paramedic delivers allocated care at call-out
Patient eligibility and capacity assessed at end of call-out 
and approached for consent if eligible
Consent for use of study and ambulance service data
Consent to be contacted about follow-up
Usual care
Paramedic consent
Trial procedure and database training
Interview and questionnaire
Follow-up consent at home and interview 
and questionnaires completed
Patient contacted about follow-up
and selected to interview and
questionnaire or questionnaire only
Patient visited and follow-up
questionnaires completed
Patient phoned and follow-up 
questionnaires completed
Follow-up questionnaires 
posted for patient to complete
Patient visited and follow-up
questionnaires completed
Patient phoned and follow-up 
questionnaires completed
Follow-up questionnaires 
posted for patient to complete
Questionnaire only
Follow-up consent at home and
questionnaires completed
Yes












FIGURE 1 BREATHE Study flowchart.
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Blinding is not possible for patient or paramedic-participants, or for members of the research team
providing intervention training, as data will be collected at interview about intervention adherence and
fidelity, and it is likely that patient-participants will indicate their allocation. The researcher conducting
interviews will collect follow-up questionnaire data before conducting the interview in order to maximise
the chances of remaining blinded to allocation until that point. After the initial follow-up visit, the
researcher will note their guess of the allocation to check if blinding is possible to take forward into the
full trial. The researcher collecting follow-up data but not interviewing participants will remain blinded to
allocation. Researchers involved in the analysis of the quantitative data will be blinded to allocation.
Intervention and comparator
This study does not interfere with routine clinical decision-making, which will be conducted according to
the JRCALC guidelines [21]. All clinical decisions regarding place of care will be taken according to the
paramedic usual practice; highly experienced professionals who make decisions regarding conveyance
daily.
Training
All paramedic-participants will receive a 1-h face-to-face study initiation training on consent and research
procedures. This will be delivered by both clinical and non-clinical members of the research team and will
include NRS training. The NRS breathlessness severity rating [22] (0=no breathlessness now; 10=worst
possible breathlessness now) will form part of clinical assessment for all patients calling with
acute-on-chronic breathlessness, irrespective of the trial. This is in line with recent calls to measure
breathlessness severity as routine clinical practice. Paramedic-participants randomised to intervention only
will receive face-to-face BREATHE intervention training delivered by clinicians on the research team.
Intervention
The BREATHE intervention is reported in accordance with the template for intervention description and
replication (TIDieR) checklist [23]. The intervention (table 2) was developed based on components of
evidence-based non-pharmacological breathlessness interventions [24] and the findings of in-depth
interviews with respiratory and emergency clinicians. It includes: 1) face-to-face advice (positioning,
breathing techniques, panic management, fan); 2) a laminated leaflet; and 3) a breathlessness management
booklet to keep and refer to later. This booklet contains information to help the patient and carer
self-manage breathlessness and information on local support services. Elements of the intervention used
during the call-out will be recorded to capture fidelity of delivery.
The BREATHE intervention has adapted everyday paramedic (first responders) practice aiming to ease
acute-on-chronic breathlessness more quickly and, where the paramedic deems appropriate, prevent
avoidable ED attendances in people living with chronic breathlessness. Following training,
paramedic-participants allocated to intervention will use the intervention (or elements of it according to
the clinical situation) during all call-outs for acute-on-chronic breathlessness irrespective of whether the
patient consents to data collection.
TABLE 1 Schedule of events for patient-participants
Visit Call-out (baseline) 48 h Day 14 Day 30 Month 6
Day 0 2 (±0 days) 14 (±7 days) 30 (±7 days) 183 (±7 days)
Procedure/assessment
Inclusion/exclusion criteria assessment x
Call-out informed consent x
NRS 0–10 breathlessness every 2 min (patient) x
Routinely collected paramedic data x
Demographic measures (patient and carer) x
Index ambulance call-out outcome x
Further call-outs in 48 h after index call-out x
Follow-up informed consent x
Interview (patient and carer) x
Health service utilisation questionnaire (patient) x x x
SF-36 (patient) x x x
CRQ-Dyspnoea Questionnaire (patient) x x x
NRS: numerical rating scale; SF-36: Short Form 36; CRQ: Chronic Respiratory Questionnaire.
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Comparator: usual care
The paramedic-participants will deliver usual care according to national guidelines including initial
history, baseline vital signs and tailored examination (chest auscultation, peak flow readings, 12-lead ECG).
Outcomes and assessments
For BREATHE, the primary end-point is the end of the index paramedic call-out. If the patient-participant
stays at home, this will be at the point the paramedic leaves the house. If the patient is conveyed to the
ED, this will be at any point up until the paramedic leaves the patient in the ED according to their clinical
judgement.
Feasibility outcomes
The primary feasibility outcomes being assessed relate to recruitment. These are paramedic-participant
and patient-participant recruitment and attrition overall, paramedics’ willingness to be randomised, patient
recruitment per paramedic and consent for Day 0 data use, and for follow-up data provision.
The following secondary feasibility outcomes will be assessed:
• Data quality: completeness of routinely collected data and of patient and proxy reported outcome
measures.
• Intervention: fidelity and adherence of the components delivered by the paramedics will be collected
during the call-out. Acceptability will be assessed during patient and paramedic interviews. Whether the
intervention continued to be used by the patient following the initial visit will be collected at 14 days,
1 month and 6 months.
Potential definitive trial primary outcomes
1) Improvement in breathlessness intensity at end of paramedic visit. NRS intensity every 2 min till
decision to transfer to ED or decision to keep at home. The 0–10 NRS is a validated measure of
TABLE 2 BREATHE intervention and usual care
Intervention Examples of techniques Supporting
evidence
Be reassured# Reassure patient and carer; a reassuring and expert presence is sometimes sufficient to start
“unwinding” escalating breathlessness
[25, 26]
Resting position Check posture; find the most comfortable and efficient position to maximise ventilation [25, 27, 28]
Exercises (breathing) Use to slow breathing rate and encourage breathing out to prevent air trapping (e.g. pursed lip
or “breathing rectangle”); pursed lip breathing also provides increased end-expiratory
pressure
[25–29]
Airflow Use hand-held fan; airflow across lower face/nasal passages can reduce breathlessness and
recovery time
[30–32]
Time# “Take it easy, nice and slow”# [25–27]
Help with fears and
worries#
Simple techniques to manage panic and fear# [25–27]
Education of patient
and carer
Information booklet and laminated card with BREATHE intervention [25–28]
Intervention points:
a) the techniques are often simultaneously delivered and tailored to the individual
b) #: denotes anxiety-focused management
c) The laminated BREATHE card, the information booklet and hand-held fan will be packaged in a “BREATHE folder” for paramedics to take





History, baseline vital signs and targeted examination (e.g. chest auscultation, peak flow,
12-lead ECG)
Reassurance Reassurance is a mainstay of high-quality patient care
Oxygen Time critical feature: oxygen saturations of <94% or less for those patients without chronic
lung diseases
Target range oxygen saturation in patients with chronic lung diseases: 88–92%
If SpO2 >92%, oxygen would not be administered
Nebuliser Depending on the initial assessment, the paramedic may ask the patient to use their own
inhalers, or proceed to nebulisation
JRCALC: Joint Royal Colleges Ambulance Liaison Committee; ECG: electrocardiogram; SpO2: oxygen saturation.
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breathlessness intensity [22], is highly correlated with Visual Analogue Scores, is more repeatable [33] and
can be provided by a proxy reporter [34]. It can be used in routine clinical practice symptom assessment.
2) Conveyance to ED (from routinely collected data). The intra-cluster coefficient and sample size
calculation for the candidate primary outcomes will be completed.
Clinical measures
Routinely collected clinical and service delivery data include pulse, respiratory rate, blood pressure, oxygen
saturation measured by pulse oximetry (SpO2) with air, SpO2 with oxygen and working impression.
Health service utilisation
This includes healthcare resource use, both primary and secondary care, use of emergency services and
self-reported use of community support services.
Health status
The SF-36 (Short Form 36) will be administered to patient-participants from which the SF-6D will be
derived. The SF-6D is a validated health status measurement tool widely used in health economic
evaluations [35].
Chronic Respiratory Questionnaire (CRQ) dyspnoea domain
This includes measurement of mastery of breathlessness [36] and is recommended in addition to a
unidimensional tool such as the NRS [37].
Sample size
As a feasibility study, a formal sample size calculation has not been performed. Sixty patient-participants
will be recruited over 6 months, 30 in each group, providing sufficient data to answer our feasibility and
desirability questions [38]. Eight paramedic-participants allows for a 20% dropout rate, with the aim of
including at least six paramedic-participants each treating 10 patient-participants, considered sufficient for
calculating the intra-cluster coefficient.
Embedded NPT study
A mixed-methods approach will be used to conduct an embedded NPT [39] informed evaluation to
explore barriers and enablers within implementing practice change domains: coherence, cognitive
participation, collective action and reflexive monitoring. Semi-structured interviews will be held with a
purposive sample of patient-participants (n=20) (including carer-participants where present). At the end
of patient-participant recruitment, all paramedic-participants will be invited to participate in
semi-structured interviews/focus groups (to explore views on study procedures/measures and issues
regarding the implementation of the BREATHE intervention) and complete a NoMAD survey asking their
opinion about whether and how the intervention could become part of routine clinical practice.
Data management
The main study database will be developed by Hull Health Trials Unit (HHTU), using the commercial
electronic data capture system, REDCap Cloud. The system uses validation and verification features which
will be used to monitor study data quality and completeness. A study monitoring plan will be developed
by HHTU who will monitor the study.
Data analysis
The trial will be reported in accordance with the CONSORT 2010 statement extension to pilot and
feasibility trials [40].
Descriptive statistics will be reported for the feasibility outcomes: paramedic recruitment rates by
ambulance station, patient-participant recruitment rate by paramedic, intervention uptake, quality of data
collection, intervention delivery and fidelity.
Baseline data and summary for candidate primary and secondary outcomes are summarised overall and by
trial arm both by randomisation and separately for participants providing data to the primary end-point.
Data will inform a potential definitive study in terms of patient/carer self-reported needs: NRS
breathlessness intensity, clinical measures assessed by paramedics, health service utilisation questionnaire,
SF-6D and mastery of breathlessness (CRQ). Variability in candidate primary measures will be calculated
and a sample size (power calculation) for the definitive trial will be estimated for each. Adverse events will
be summarised descriptively.
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Missing data will be described but not imputed. No statistical comparisons between treatment groups will
be undertaken on baseline or follow-up data as the trial is not designed to test effectiveness.
The quality of data collection for the SF-6D (derived from the SF-36) and health service utilisation
information will be reported descriptively; however, quality-adjusted life-years (QALYs) will not be calculated.
Interview data will be analysed using framework analysis with reference to NPT [39] to determine
acceptability and feasibility of a definitive trial and barriers and facilitators to implementation. Interview/
focus group data will be analysed using NPT as a deductive framework whilst allowing for the inductive
identification of themes.
NoMAD survey data will be presented using descriptive statistics.
Stop–go criteria
Stop–go criteria (table 3) will be used to assess the key feasibility objectives of recruitment and
intervention adherence as to inform whether a main trial is possible and whether the design or other
issues needs modification in order to conduct it successfully. Remediable barriers and their solutions will
be identified from the NPT study. Process data will be used to describe interpreted timelines to identify
“fixable”, “manageable” and “insurmountable” challenges to site opening, training, data collection and
intervention fidelity with regard to both the future main trial and clinical implementation in the event of a
positive trial.
Ethics and dissemination
Regulatory approvals and trial oversight
The trial protocol has been reviewed and approved by the Yorkshire and The Humber–Sheffield Research
Ethics Committee (REC reference: 19/YH/0314). The University of Hull is the study sponsor, and the
HHTU is supporting trial delivery. A Trial Management Group has been convened to oversee trial delivery
and operations. An independent Trial Steering Committee will provide overall supervision for the project
on behalf of the Project Sponsor and Project Funder.
Safety considerations and adverse event reporting
Adverse event reporting is defined in the full study protocol. In the emergency clinical context, full safety
reporting of adverse events (AEs) and serious adverse events (SAEs) will be limited to events that occur
during the call-out visit. Because of the inherent limitation in collecting AE and SAE outcomes,
proxy-safety data relating to the number and outcome of further ambulance call-outs in the 48-h period
after the index visit will be collected using routinely collected data. In addition, the study will collect
health resource utilisation information at the 14-day, 30-days and 6-month follow-up time points.
Dissemination
The study results will be disseminated to the appropriate stakeholders through presentations, conferences
and peer-reviewed journals according to the BREATHE publication and dissemination policy.
TABLE 3 Stop–go criteria
Recruitment
Green If ⩾80% of target patient-participants are recruited to target
Amber Between ⩾60% and <80% patient-participants recruited and remediable barriers identified
and addressed in main trial protocol
Red <60% of the estimated sample size for a full trial cannot be completed by 24 months
Intervention adherence#
Green ⩾75%
Amber ⩾50 and <75%; possible if further modelled for the main trial protocol by addressing
remediable factors
Red <50%; it would be concluded that the intervention cannot be sufficiently implemented in
practice and a main trial not possible
Green: main trial feasible; amber: feasible with remediable factors addressed; red: main trial not feasible.
#: eligible patient-participants attended by a paramedic allocated to and trained in the intervention
received the intervention.
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Discussion
Providing it is found that delivering the BREATHE intervention is acceptable, feasible and desirable, the
results will inform the number of paramedic clusters required, most appropriate primary outcome and the
structure of a future definitive cluster randomised controlled trial in breathlessness patients.
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